Gut-Derived Molecule Linked to Increased Alzheimer’s Risk: New Insights

A recent study sheds light on the role of a molecule produced by gut bacteria in the progression of Alzheimer’s disease. Conducted by researchers from the University of Wisconsin-Madison, this work suggests that imidazole propionate (ImP) could be instrumental in understanding cognitive decline tied to dementia.

Nearly ten years ago, a team from UW-Madison led by Barbara Bendlin and Federico Rey identified differences in gut microbiota between individuals with Alzheimer's and healthy counterparts. Bendlin, a professor in the UW School of Medicine and Public Health, stated, “Since then, we’ve been trying to figure out how these differences influence brain health.”

The team's latest findings, published in Nature Communications, focus on ImP—a compound associated with certain gut bacteria. Their research indicates that ImP may exacerbate brain changes integral to Alzheimer’s and similar dementias.

Variability of ImP Production

The production of ImP varies widely among individuals, with some generating significant amounts while others produce negligible levels. Rey, a professor of bacteriology, pointed out, “ImP-producing bacteria are found in many people, but they’re not necessarily abundant. Still, a single microbe can have a notable impact.”

Once synthesized in the gut, ImP can enter the bloodstream, reaching the brain and potentially contributing to conditions like type 2 diabetes and coronary artery disease, according to previous research. The new study highlights ImP's alarming connection to neurodegeneration. In experiments with mice, researchers observed that ImP reaching the brain led to increased accumulation of abnormal beta amyloid and tau proteins—hallmarks of Alzheimer’s-related damage.

Cognitive Decline and Genetic Factors

In another critical aspect of the study, researchers analyzed blood samples from around 1,200 individuals involved in the Wisconsin Registry for Alzheimer's Prevention. Those with elevated ImP levels exhibited more pronounced biological markers of neuron impairment and abnormal protein buildup.

Furthermore, the data correlated higher ImP levels with accelerated cognitive decline. “Thanks to cognitive tests over time, we noticed that participants with elevated ImP levels also experienced notably quicker cognitive deterioration,” Rey noted.

The researchers identified a specific genetic variant present in roughly 43% of participants, which they suspect influences kidney efficiency in filtering out ImP. Rey indicated that this genetic factor has been tied to increased Alzheimer’s risk in larger genetic studies, shedding light on its relationship with ImP levels.

Potential for Targeted Treatments

The findings open an intriguing avenue for targeting ImP in Alzheimer’s prevention strategies. Adjusting dietary intake of histidine, the amino acid from which ImP is derived, isn’t straightforward; histidine is abundant in many nutritious foods. Bendlin commented, “Improving one's diet might help, but it’s not a simple task like saying, ‘eliminate eggs’ or ‘cut down on red meat.’”

Instead, researchers suggest that focusing on treatments aimed at lowering ImP in the bloodstream might prove more effective. Identifying both the molecule and its related gene variant offers a precise goal for future research.

“The situation resembles cholesterol management,” Bendlin explained. “Just as those with high cholesterol may take statins to mitigate heart disease risk, finding an inhibitor that curtails ImP levels could be pivotal in reducing Alzheimer’s risk and slowing cognitive decline for many.”

Additional contributions to this research came from teams at the University of California, Los Angeles and the University of Gothenburg, highlighting a collaborative effort to uncover the nexus between gut health and neurodegenerative diseases.

This research was supported by grants from various institutions, including the Wisconsin Partnership Program and the National Institutes of Health. These insights not only highlight the intricate relationship between gut health and brain function but also pave the way for targeted interventions that could alter the course of Alzheimer’s disease.

Learn more about the study conducted by the University of Wisconsin-Madison. Original report by Chris Barncard.